Posted by XanyADDam on February 1, 2007, at 2:51:14
In reply to Updates on pipeline drugs?, posted by jealibeanz on January 31, 2007, at 9:49:43
> Has anyone heard any news about the upcoming depression/anxiety drugs in stage III by Sanodi-Aventis? There's an NK1 receptor antagonist and a beta-3 adrenoreceptor blocker. The later seems to be further along. Any word?
Yeah...I checked out http://www.neurotransmitter.net/newdrugs.html. The drugs you were referring to, SR 58611 and Saredutant (SR 48968)...SR 58611 is a selective beta-3-adrenoceptor agonist, used to treat depression and anxiety. As far as its development phase: A supplemental NDA is possible in 2007. Saredutant, an NK2 antagonist, has been indicated in the treatment of depression and anxiety as well. It is, as you stated, currently in Phase III.
poster:XanyADDam
thread:728407
URL: http://www.dr-bob.org/babble/20070125/msgs/728666.html